188 related articles for article (PubMed ID: 32047167)
61. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
[TBL] [Abstract][Full Text] [Related]
62. Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma.
Khan SN; Swiecicki PL; Doroshow DB
Cancer J; 2022 Sep-Oct 01; 28(5):381-386. PubMed ID: 36165727
[TBL] [Abstract][Full Text] [Related]
63. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents.
Lingen MW
Crit Rev Oral Biol Med; 1999; 10(2):153-64. PubMed ID: 10759419
[TBL] [Abstract][Full Text] [Related]
64. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
[TBL] [Abstract][Full Text] [Related]
65. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
[TBL] [Abstract][Full Text] [Related]
66. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
67. Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.
Chen J; Jia X; Li Z; Song W; Jin C; Zhou M; Xie H; Zheng S; Song P
Biochem Pharmacol; 2021 Jun; 188():114494. PubMed ID: 33684390
[TBL] [Abstract][Full Text] [Related]
68. Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases.
Webster PJ; Littlejohns AT; Gaunt HJ; Young RS; Rode B; Ritchie JE; Stead LF; Harrison S; Droop A; Martin HL; Tomlinson DC; Hyman AJ; Appleby HL; Boxall S; Bruns AF; Li J; Prasad RK; Lodge JPA; Burke DA; Beech DJ
Oncotarget; 2017 Jun; 8(26):42288-42299. PubMed ID: 28178688
[TBL] [Abstract][Full Text] [Related]
69. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
70. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
71. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K
J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086
[TBL] [Abstract][Full Text] [Related]
72. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death.
van Harten AM; Buijze M; van der Mast R; Rooimans MA; Martens-de Kemp SR; Bachas C; Brink A; Stigter-van Walsum M; Wolthuis RMF; Brakenhoff RH
Oncogenesis; 2019 Jun; 8(7):38. PubMed ID: 31209198
[TBL] [Abstract][Full Text] [Related]
73. PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.
Brunner A; Suryo Rahmanto A; Johansson H; Franco M; Viiliäinen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtiö J; Rantala JK; Larsson LG; Sangfelt O
Elife; 2020 Jul; 9():. PubMed ID: 32628111
[TBL] [Abstract][Full Text] [Related]
74. Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA.
Zhang X; Cai A; Gao Y; Zhang Y; Duan X; Men K
Mol Pharm; 2021 Sep; 18(9):3387-3400. PubMed ID: 34375118
[TBL] [Abstract][Full Text] [Related]
75. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Martens-de Kemp SR; Nagel R; Stigter-van Walsum M; van der Meulen IH; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Clin Cancer Res; 2013 Apr; 19(8):1994-2003. PubMed ID: 23444224
[TBL] [Abstract][Full Text] [Related]
76. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.
Magnussen GI; Holm R; Emilsen E; Rosnes AK; Slipicevic A; Flørenes VA
PLoS One; 2012; 7(6):e38254. PubMed ID: 22719872
[TBL] [Abstract][Full Text] [Related]
77. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
78. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
[TBL] [Abstract][Full Text] [Related]
79. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Hasina R; Hulett K; Bicciato S; Di Bello C; Petruzzelli GJ; Lingen MW
Cancer Res; 2003 Feb; 63(3):555-9. PubMed ID: 12566295
[TBL] [Abstract][Full Text] [Related]
80. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.
Pouliot LM; Chen YC; Bai J; Guha R; Martin SE; Gottesman MM; Hall MD
Cancer Res; 2012 Nov; 72(22):5945-55. PubMed ID: 22942255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
